biostudies-literatureUnknown24(1)Cartlidge MK<h4>Background</h4>Drugs used to treat rheumatic disease are associated with pneumotoxicity (drug-induced lung disease), but little is known about associated risk factors.<h4>Aim</h4>To determine expert physician-perceived risk factors for developing pneumotoxicity in patients with rheumatologic conditions.<h4>Methods</h4>A modified international 3-tier Delphi exercise was performed. Tier 1 determined patient and drug variables that physicians perceive to be risk factors. Tier 2 determined degree of risk associated with the Tier-1 derived variables. Tier 3 aimed to internally validate and stratify exemplar cases into risk categories.<h4>Results</h4>134 pulmonologists and 49 rheumatologists responded to Tier 1;157 physicians completed all tiers. Perceived risk factors included: drug type; hBMC pulmonary medicine547https://www.ebi.ac.uk/biostudies/studies/S-EPMC11529426biostudies-literatureA modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease.PMC11529426Johannson KABusaid NAHyldgaard CLipchik RJCorte TJJohn LMatsuda TNossent EJTanino YSolomon JJPerch MBlum HCBendstrup ERoss ADFoti RBrown KKChaigne BBilaceroglu SDhasmana DJNunes MSStewart GSebastiani MHysa EJones MGEiger GGrainger RDerrett-Smith ENaclerio CRadzikowska EGheorghiu AMPapanikolaou ICAssaya DMaher TMSehga SO'Beirne SLAntin-Ozerkis DDieude PRivera-Ortega PRussell TNunes HMukherjee SBrito de Araujo DKiyan EMyall KJRamirez MTRPerkovic DHajari Case ACeribelli AMcRorie ENicol LGarcia Martos AManfredi ABorie RAmaral AFConfalonieri PKelly CFerreira PGuillen AGodoyCastillo DTomii KChalmers GWTurner AMWuyts WALuckhardt TKalyoncu AFChaudhuri NIzumi SVikse JWilsher MLGrazzini SIudici MAgrawal AKabasakal YMontoya SFAl-Farttoosi ABaresic MSelvi ERosato EBerlengiero VMorovic-Vergles JSelva-O'Callaghan AShifren ABenucci MDelobbe AKeshavan VGabrielli ACamus PSpencer LGCarreira PEJones RMSaunders PBalbir-Gurman ADavidsen JRCampainha SWaseda YKalluri MCobilinschi CAvdeev SPatil SBernardino VChaudhury NWalker UAToma CLNovelli LBalestro EAlfaro TDevi HJGWijsenbeek MGolla Jvan der Lee ILaunay DRednic SDrakopanagiotakis FCrestani BPatel DCMuller CGarzanova LJudge EPPadilla MLWalsh SLFGardiner PVChai GTKoduri GMScarlata SGudmundsson GKhanna DSalinas MMogulkoc NMdC VVicens-Zygmunt VLopez Miguel PRyerson CJLow SYFretheim HParfrey HCampochiaro CFahim ACulver DELStebbings SMCastro HMStewart GAReza Beiga DMCrawshaw AConticini EBennett DJuge PACarbone RGSaiton SHirani NCarty SMKolb MCameli PCartlidge MKPASSWRD participantsKah-Lai Leong CChua FMarovic KFSulli ADzhus MNicol LMGarcia Gonzalez EHighland KBRobles-Perez AfalseA modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease.<h4>Background</h4>Drugs used to treat rheumatic disease are associated with pneumotoxicity (drug-induced lung disease), but little is known about associated risk factors.<h4>Aim</h4>To determine expert physician-perceived risk factors for developing pneumotoxicity in patients with rheumatologic conditions.<h4>Methods</h4>A modified international 3-tier Delphi exercise was performed. Tier 1 determined patient and drug variables that physicians perceive to be risk factors. Tier 2 determined degree of risk associated with the Tier-1 derived variables. Tier 3 aimed to internally validate and stratify exemplar cases into risk categories.<h4>Results</h4>134 pulmonologists and 49 rheumatologists responded to Tier 1;157 physicians completed all tiers. Perceived risk factors included: drug type; h2024-01-01T00:00:00Z2024 Oct2025-04-05T09:14:19.829Z2025-04-05T09:14:19.829ZS-EPMC115294263948264410.1186/s12890-024-03287-0